Biotech Values

[Swick984]

ALBO - For those interested in ALBO and their odevixibat pediatric liver disease franchise, this may be a good entry point. Analysts have attributed no value to the NASH opportunity and management had always considered elobixibat as a stretch in NASH, potentially in partnership with another drug. Phase 3 data on the odevixibat PFIC indication should be out in the next few weeks and will be the key driver of valuation. Perceptive Advisors owns a stake and added in the company's latest capital raise.